Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

Renal Insufficiency, Chronic Clinical Trial

— MRA-ACE  

Official title:

Safety and Efficacy of Maximally Tolerated RAAS Blockade and Spironolactone Therapy on Urinary Proteinuria and Progression of Type II Diabetic Nephropathy in African Americans and Other Patient Cohorts.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03502031
• Other study ID #: NN-01
• Status: Recruiting
• Phase: Phase 4
• Start date: October 1, 2018
• Est. completion date: October 1, 2024

Study information

• Verified date: October 2022
• Source: NephroNet, Inc.
• Contact: James A Tumlin, MD
• Phone: 770-490-9203
• Email: jamestumlinmdnephronet[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

NephroNet proposes to examine whether combining Spironolactone with maximal RAAS blockade will further reduce urinary protein at one year and whether prolonged therapy (24 months) is able to slow the decline in GFR. Because of combination MRA and RAAS therapy significantly increases the risk for clinically significant hyperkalemia, we also plan to determine whether the addition of Patiromer to these patients facilitates the use of combination therapy and allows a larger proportion of diabetic patients the potential benefit of combination therapy on renal function.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72
• Est. completion date: October 1, 2024
• Est. primary completion date: October 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

• Age above 18

• Male or Female

• Patients with Type II diabetes mellitus must be receiving oral agents or insulin injections at the time of randomization

• All eligible patients will be on a stable, maximum to dose of an ACE or ARB for 2 weeks prior to randomization.

• Note: The determination of m tolerated ACE-ARB therapy will be left to the discretion of the site princ

• All eligible patientswill have hypertension targetblood pressur of < 140/90mm Hg.

• Antihypertensiv therapy may be adjusted to achieve the target blood pressure prior to the time of randomization.

• ACE or ARB therapy will be the primary antihypertensive therapy used for blood pressure control and will be titrthe highest tolerated dose to achieve a target blood pressure of <Patients requiring additional medications to achieve the target blood pressure will use antihypertensive agents that have neutral effects on urinary proteinuria (e.g. Hydralazine or lo Dihydropyridine calcium channel blockers etc.). CcThe final choice of additional medications will be left to the discretion of the site principal investigator (PI)

• Patients with anurine protein to creatinine (UP/Cr) ratio that is mg/gm from the average of two historical value within one year prior to randomization will be considered eligible for study entry.

• Patients with a baseline K+ of >5. X5 meq/l on maximum tolerated ACE-ARB therapy during the screening period can be treated with 8.4 grams of Patiromer for 7 days. If at the end of 7days the serum K+ is < 5.0 meq/liter the patient will be considered eligible to participate in the study. If at the end of 7 days the serum K+ >5.0 meq/l the dose of Patiromer can be increased to 16.8 grams. If at the end of 7 days the serum K+ is < 5.0 meq/L, the patient will be considered eligible for study entry. If after 7 days at the higher dose of Patiromer the serum K+ >5.0, the patient will be ineligible for study participation.

• Patients with an estimated GFR by CK-Epi .73 m2

• Female patients will be required to undergo routine birth control measures

Exclusion criteria:

• Estimated GFR by MDRD20 mls/min/1.73 M2 using the CKD-Epi equation

• Patients with serum K+ > 5.00 while taking 16.8/day of Patiromer

• Patients with history of Type mellitus

• Patients with HgbA

• Pregnant or breast-feeding female patients

• Female patients unwilling to receive estrogen or progesterone based birth control or are unwilling or unable to usconventional barrier birth control methods.

• Patients with known allergy or intolerance tor Spironolactone therapy

• Patients taking oral or IV digoxin

• Patients receiving chronic steroids > 1oral Prednisone

• Patient that do nohave minimum o eGFR determinations within 2 years prior to study randomization

• Concurrent use of Amiloride, , Aliskerin, or other Aldosterone antagonists Patien receiving any of the above medications will be considered eligible for study participation after a wash-out

Related Conditions & MeSH terms

• Diabetic Nephropathies
• Diabetic Nephropathy Type 2
• Kidney Diseases
• Renal Insufficiency
• Renal Insufficiency, Chronic

Intervention

Drug:
• Renin-Angiotensin (RAAS) alone
maximal RAAS blockade alone for 24months.
• Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 24 months.

Locations

Country	Name	City	State
United States	Nelson Kopyt, MD	Bethlehem	Pennsylvania
United States	Georgia Nephrology Research Institute	Lawrenceville	Georgia

Sponsors (2)

Lead Sponsor	Collaborator
James A. Tumlin, MD	Nelson Kopyt, MD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Combination Therapy - RAAS inhibition and Spironolactone to lower UP/Cr	To determine whether combination therapy with maximall RAAS inhibition and Spironolactone is superior to RAAS inhibition alone in lowering the UP/Cr ratio at 12 months	24 months
Secondary	Combination Therapy - RAAS inhibition and Spironolactone	To determine whether combination therapy with maximally tolerated RAAS inhibition and Spironolactone is superior to RAAS inhibition alone in slowing the progression of renal disease as evidenced by changes in GFR	24 months
Secondary	Combination Therapy - RAAS inhibition and Spironolactone that develop hyperkalemia	To determine the patients in the maximal RAAS blockade group and those receiving combination RAAS + Spironolactone therapy developing clinically significant hyperkalemia as defined as a serum K+ level greater than 5.5 meq/L. We will determine the percentage of patients that require "Patiromer-Rescue" for K+ > 5.5 meq/L and the percentage of patients maintained with serum K+ less than 5.5 meq/L	12 months, 24 months